GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA (SIEWERT II-III)

Clinical trials for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA (SIEWERT II-III) explained in plain language.

Never miss a new study

Get alerted when new GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA (SIEWERT II-III) trials appear

Sign up with your email to follow new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA (SIEWERT II-III), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

Scientists probe tumor environment to predict drug resistance in stomach cancer

Knowledge-focused Not yet recruiting

This study investigates why some stomach cancers do not respond to a standard chemotherapy combination (FLOT) plus the immunotherapy drug durvalumab. Researchers will analyze tumor samples and blood from 250 patients with operable stomach or gastroesophageal junction cancer. By m…

Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA (SIEWERT II-III)

Sponsor: Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis • Aim: Knowledge-focused

Last updated Jul 11, 2026 00:00 UTC

GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA (SIEWERT II-III)

Get alerted when new GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA (SIEWERT II-III) trials appear

Scientists probe tumor environment to predict drug resistance in stomach cancer